BBUSvsPBE
JPMorgan BetaBuilders U.S. Equity ETF against Invesco Dynamic Biotechnology & Genome ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BBUS | PBE | |
|---|---|---|
| Expense ratio | 0.020% | 0.58% |
| Assets | $9.3B | $424M |
| Net flow, 1 month | +$242M | −$55M |
| Net flow, 1 year | +$2.6B | +$114M |
| Return, YTD | +12.7% | +15.7% |
| Return, 1 year | +14.6% | +32.0% |
| Avg daily volume | 260K | 18K |
| Holdings | 575 | 31 |
| Listed | Mar 11, 2019 | Jun 23, 2005 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS